Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Marker Therapeutics (MRKR) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Marker Therapeutics (MRKR) over the last 11 years, with Q3 2025 value amounting to 0.85.

  • Marker Therapeutics' Equity Ratio rose 2391.0% to 0.85 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.85, marking a year-over-year increase of 2391.0%. This contributed to the annual value of 0.84 for FY2024, which is 270.78% up from last year.
  • As of Q3 2025, Marker Therapeutics' Equity Ratio stood at 0.85, which was up 2391.0% from 0.71 recorded in Q2 2025.
  • Marker Therapeutics' 5-year Equity Ratio high stood at 0.87 for Q2 2023, and its period low was 0.54 during Q2 2022.
  • In the last 5 years, Marker Therapeutics' Equity Ratio had a median value of 0.79 in 2021 and averaged 0.74.
  • As far as peak fluctuations go, Marker Therapeutics' Equity Ratio plummeted by 3184.08% in 2022, and later skyrocketed by 6184.57% in 2023.
  • Quarter analysis of 5 years shows Marker Therapeutics' Equity Ratio stood at 0.65 in 2021, then fell by 11.79% to 0.57 in 2022, then surged by 44.09% to 0.82 in 2023, then rose by 2.71% to 0.84 in 2024, then increased by 0.4% to 0.85 in 2025.
  • Its Equity Ratio was 0.85 in Q3 2025, compared to 0.71 in Q2 2025 and 0.85 in Q1 2025.